// App-Quantinova.ai

TPS5601 : Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.

Researchers

Presenter

  • Brittany Anne Davidson

Principal Investigators

  • Robert Squatrito

  • Linda R. Duska

  • Laura Jean Havrilesky

  • Nyssa Schwager

  • Michael McCollum

  • Sanja Arapovic

  • Angeles Alvarez Secord

Medical Centers

  • Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Virginia Oncology Associates, Norfolk, VA

  • University of Virginia Medical Center, Charlottesville, VA

  • Duke University Medical Center, Durham, NC

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peritoneal cancer

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • Vascular endothelial growth factor A

  • Carbohydrate antigen 125

Drug/Treatment

  • Bevacizumab

  • Nintedanib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT01669798

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved